Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.64 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.57 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.57 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6370948 | 0.90 | TRPV1 (0.64) | TRPV1GRIK1KMT2AMEN1MAPT | |
| SCHEMBL1463622 | 0.85 | TRPV1 (0.70) | TRPV1GRIK1KMT2AMEN1MAPT | |
| SCHEMBL26697304 | 0.82 | KDR (0.74) | TRPV1GRIK1KMT2AMEN1MAPT | |
| SCHEMBL3676521 | 0.82 | TRPV1 (0.67) | TRPV1GRIK1KMT2AMEN1MAPT | |
| SCHEMBL1463509 | 0.82 | GRIK1 (0.77) | TRPV1GRIK1KMT2AMEN1MAPT | |
| SCHEMBL1463407 | 0.82 | NTRK1 (0.77) | TRPV1GRIK1KMT2AMEN1MAPT | |
| SCHEMBL6376812 | 0.80 | KMT2A (0.79) | TRPV1GRIK1KMT2AMEN1MAPT | |
| SCHEMBL6371123 | 0.80 | TRPV1 (0.67) | TRPV1GRIK1KMT2AMEN1MAPT | |
| SCHEMBL5597699 | 0.80 | KMT2A (0.90) | GRIK1KMT2AMEN1MAPTHTT | |
| SCHEMBL30101230 | 0.80 | KMT2A (0.90) | GRIK1KMT2AMEN1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1904498-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007004749-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | TRPV1 918/4885GRIK1 4183/4885KMT2A 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.